PB0431 - Insights on Venous Thromboembolism and Antiphospholipid antibody syndrome by 1H-NMR

Sunday, June 25, 2023

18:30 – 19:30 ET

Room: Exhibition

Co-Author(s)

LM

Lucas Martins

Researcher
Department of Organic Chemistry, Institute of Chemistry, University of Campinas, Campinas, São Paulo, Brazil
Campinas, Sao Paulo, Brazil
BM

Bruna Manzini

Pos-doc
Laboratory of Hemostasis, HEMOCENTRO-UNICAMP, University of Campinas, Campinas, São Paulo, Brazil.
Campinas, Sao Paulo, Brazil

Presenting Author(s)

Silmara L. Montalvao, PhD (she/her/hers)

Responsible for the Haemostasis Laboratory
Hemocentro UNICAMP, University of Campinas, Campinas, SP, Brazil
Campinas, Sao Paulo, Brazil

Co-Author(s)

MH

Millene Honorato

Master student
Laboratory of Hemostasis, HEMOCENTRO-UNICAMP, University of Campinas, Campinas, São Paulo, Brazil.
Campinas, Sao Paulo, Brazil
MC

Marina P. P. Colella

Hematologist
Hemocentro UNICAMP, University of Campinas, Campinas, SP, Brazil
Campinas, Sao Paulo, Brazil
Gabriela G. Yamaguti-Hayakawa, MD, PhD (she/her/hers)

Hematologist
Hemocentro UNICAMP, University of Campinas, Campinas, SP, Brazil
Campinas, Sao Paulo, Brazil
Erich V. Vinicius de Paula, MD, PhD (he/him/his)

Professor
University of Campinas
Campinas, Sao Paulo, Brazil
FO

Fernanda A. Orsi

Hematologist
University of São Paulo Medical School
São Paulo, Sao Paulo, Brazil
EB

Erik Braga

student
Department of Organic Chemistry, Institute of Chemistry, University of Campinas, Campinas, São Paulo, Brazil
Campinas, Sao Paulo, Brazil
NA

Natasa Avramovic

Professor
University of Belgrade, Faculty of Medicine, Institute of Medical Chemistry, Belgrade, Serbia.
Belgrade, Kosovo, Serbia
LT

Ljubica Tasic

Professor
Department of Organic Chemistry, Institute of Chemistry, University of Campinas, Campinas, São Paulo, Brazil
Campinas, Sao Paulo, Brazil

Co-Author(s)

JA

Joyce Annichino-Bizzacchi

Professor of Hematology
Laboratory of Hemostasis, HEMOCENTRO-UNICAMP, University of Campinas, Campinas, São Paulo, Brazil.
Campinas, Sao Paulo, Brazil

Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent arterial or venous thrombosis or obstetrical morbidities accompanied by antiphospholipid antibodies (aPLs). APS pathophysiology is complex, containing several pathogenic mechanisms related to coagulation, endothelium, and platelets, which may increase the risk of thromboembolic complications. Metabonomics allows the understanding of the metabolites function in the organism, giving important information about biological pathways that are compromised by the disease or lead to alterations linked to it.

Aims: This study aimed to diagnose venous thromboembolism (VTE). Through NMR-based metabonomics, investigate sera metabolic profiles of the thrombotic patients' group without APS and the thrombotic primary APS group (PAPS), compared to healthy control (HC). Also, the comparison of metabolic profiles of VTE with the thrombotic PAPS group was explored.

Methods: The studied population consisted of patients assisted at the outpatient Clinic of Hemocentro of Unicamp (Campinas, SP, Brazil) between 2009 and 2020. Inclusion criteria were objectively diagnosis and age above 16 years. Exclusion criteria were secondary APS, infection, rheumatologic, renal, hepatic, or inflammatory disease, and corticosteroids use. Serum samples of patients with arterial or VTE without APS (n=32), PAPS (n=32), and HC (n=32) were analyzed. APS diagnosis was defined by persistently positive aPL. Thrombotic APS patients were matched by age and gender to VTE without APS and HC.

Results: Differences were observed in metabolic profiles between VTE and HC, PAPS and HC (Figure 1), as well as between VTE and triple-positive PAPS groups (Figure 2). The changes in metabolites indicated important alterations in metabolic pathways of glycolysis, TCA cycle, lipid metabolism, and branched-chain amino acid (BCAA) metabolism. Significant alteration in metabolomic profiles pointed to complex pathogenesis mechanisms of PAPS and VTE.

Conclusion(s): These metabolites might be potential biomarkers to differentiate PAPS and VTE patients, including the parameter of aPLs for APS patients.